10X GENOMICS INC-CLASS A (TXG)
US88025U1097 - Common Stock
Taking everything into account, TXG scores 4 out of 10 in our fundamental rating. TXG was compared to 58 industry peers in the Life Sciences Tools & Services industry. TXG has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, TXG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TXG has reported negative net income.
TXG had a negative operating cash flow in the past year.
TXG had negative earnings in each of the past 5 years.
TXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -28.64%, TXG is doing worse than 75.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of -36.77%, TXG is doing worse than 68.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.64% | ||
| ROE | -36.77% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TXG has a better Gross Margin (64.62%) than 91.38% of its industry peers.
In the last couple of years the Gross Margin of TXG has declined.
TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXG has more shares outstanding
TXG has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.76 indicates that TXG is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.76, TXG belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.76 |
ROIC/WACCN/A
WACC12.29%
2.3 Liquidity
A Current Ratio of 5.22 indicates that TXG has no problem at all paying its short term obligations.
The Current ratio of TXG (5.22) is better than 74.14% of its industry peers.
A Quick Ratio of 4.45 indicates that TXG has no problem at all paying its short term obligations.
The Quick ratio of TXG (4.45) is better than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.22 | ||
| Quick Ratio | 4.45 |
3. Growth
3.1 Past
TXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.75%.
Looking at the last year, TXG shows a quite strong growth in Revenue. The Revenue has grown by 16.63% in the last year.
Measured over the past years, TXG shows a very strong growth in Revenue. The Revenue has been growing by 33.43% on average per year.
EPS 1Y (TTM)-45.75%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.64%
Revenue 1Y (TTM)16.63%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Revenue growth Q2Q4.99%
3.2 Future
Based on estimates for the next years, TXG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.66% on average per year.
The Revenue is expected to grow by 12.60% on average over the next years. This is quite good.
EPS Next Y25.05%
EPS Next 2Y25.04%
EPS Next 3Y24.17%
EPS Next 5Y24.66%
Revenue Next Year10.05%
Revenue Next 2Y13.57%
Revenue Next 3Y14.75%
Revenue Next 5Y12.6%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TXG's earnings are expected to grow with 24.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.04%
EPS Next 3Y24.17%
5. Dividend
5.1 Amount
No dividends for TXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10X GENOMICS INC-CLASS A
NASDAQ:TXG (5/13/2024, 7:00:02 PM)
After market: 26.97 0 (0%)26.97
+0.98 (+3.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.23B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.64% | ||
| ROE | -36.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.62% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.22 | ||
| Quick Ratio | 4.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-45.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.63%
Revenue growth 3Y27.46%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y